Celgene Shows Off Crohn's Disease Data in Small Mid-Stage Study
Celgene Corp.’s experimental pill for Crohn’s disease helped more patients than analysts expected, reinforcing positive results of an earlier study and likely boosting investors’ confidence in the drug’s chances of approval.
Thirty-seven percent of patients saw an improvement of 25 percent or higher in a score measuring gut health after taking the drug, called GED-0301, Celgene said Sunday in a statement. Experts are looking for a quarter or more of patients to see that improvement, according to RBC Capital Markets analyst Michael Yee.
Thirty-seven percent of patients saw an improvement of 25 percent or higher in a score measuring gut health after taking the drug, called GED-0301, Celgene said Sunday in a statement. Experts are looking for a quarter or more of patients to see that improvement, according to RBC Capital Markets analyst Michael Yee.